Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;19(12 Suppl 9):3-4.

Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis at 8-16 Weeks: A Multicenter Retrospective Cohort Study

No authors listed

Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis at 8-16 Weeks: A Multicenter Retrospective Cohort Study

No authors listed. Gastroenterol Hepatol (N Y). 2023 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 2.
Figure 2.
Outcomes from a multicenter retrospective cohort study comparing patients with ulcerative colitis treated with upadacitinib vs ustekinumab. Adapted from Dalal et al. Abstract 72. Presented at: ACG 2023; October 20-25, 2023; Vancouver, Canada.
See this image and copyright information in PMC

References

    1. Sands BE, Sandborn WJ, Panaccione R et al. UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. - PubMed
    1. Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113–2128. - PubMed
    1. Dalal RS, Mitri J, Goodrick H, Allegretti JR. Real-world comparison of tofacitinib vs ustekinumab among bio-exposed patients with ulcerative colitis: a propensity score analysis. Inflamm Bowel Dis. 2021;27(10):1694–1697. - PMC - PubMed
    1. Dalal RS, Kallumkal G, Cabral HJ Comparative effectiveness of upadacitinib vs ustekinumab for ulcerative colitis at 8-16 weeks: a multicenter retrospective cohort study. Abstract 72. 2023. Presented at: ACG 2023 Annual Scientific Meeting; October 20-25. Vancouver, Canada.

LinkOut - more resources